Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech

Executive Summary

Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.

Advertisement

Related Content

VC Deals Analysis: Liquid Biopsy Summons Yet Another Top A-Lister
Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market
Device/Diagnostics Quarterly Deal Statistics, Q3 2016
Pacts In Medtech, July/August 2016
In Vivo's Deals Of The Month, August 2016
Google Broadens Diabetes Reach With Dexcom Partnership
Google and Novartis in smart lens pact
GSK pumps $50m into new-gen neuromodulation techs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT103665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel